Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2761 to 2775 of 7688 results

  1. Technology appraisal data

    Explore data about our technology appraisal guidance

  2. Data collection agreement

    This agreement relates to treating cystic fibrosis patients with: Ivacaftor, tezacaftor and elexacaftor (Kaftrio®) in combination with ivacaftor for

  3. Technology appraisal methods and processes used before 2022

    We use 3 processes for assessing technologies: the single technology appraisal, the multiple technology appraisal and the fast track appraisal.

  4. MTA process timeline

    These are the main stages in the multiple technology appraisal process used before April 2018. It applies to evaluations that started before 1...

  5. STA process timeline, pre-April 2018

    These are the main stages in the single technology appraisal (STA) process used before April 2018.

  6. Chemotherapy dose standardisation: NICE position statement

    NICE has been collaborating with NHS England on the Chemotherapy Dose Standardisation initiative which has been developed by the Medicines...

  7. Types of technology appraisal recommendation

    The technology appraisal committee can make 5 types of recommendation: Recommended, Optimised, Recommended for use in the Cancer Drugs Fund, Only in research, and Not recommended.

  8. Position statement on use of the EQ-5D-5L value set for England (updated October 2019)

    Our position on use of the EQ-5D-5L valuation set for England

  9. Modular updates for our technology appraisal guidance

    On this page, you'll find all our modular updates relating to our technology appraisal guidance. October 2023 NICE response to consultation on the...

  10. Biosimilar technologies: NICE position statement

    There are 2 different points of the lifecycle of a NICE Technology Appraisal at which consideration of reference to or inclusion of a biosimilar is...

  11. Biosimilar technologies: NICE position statement - information for the public

    Biosimilar medicines – NICE's approach A biological medicine is any medicinal product made by or derived from a biological (natural) source, for...

  12. Management of inflammatory arthritis

    All forms of inflammatory arthritis have similar management strategies coordinated through a multidisciplinary team. Pharmacological treatments are...

  13. Osteoarthritis

    Osteoarthritis refers to a condition where there is joint pain accompanied by functional limitation and reduced quality of life. It mainly affects...

  14. What is NICE doing next?

    Throughout this report we have highlighted examples showing how uptake of our guidance has contributed to improvements in arthritis care. Improvements

  15. NICE impact cardiovascular disease management

    Find out about the progress made by the health and care system in implementing NICE guidance on cardiovascular disease management